卜宪章

卜宪章

教授

研究领域：药学多学科融合基础上的药物设计与发现：
1.活性多肽、类天然产物库的构建；
2.肿瘤、神经退行性疾病恶性事件中关键蛋白的降解与折叠行为调控及药理意义；
3.重大疾病相关信号网络关键因子的探针设计与药物发现

办公电话： +8620-39943054

联系邮箱： phsbxzh@mail.sysu.edu.cn

简介

博士，教授，博士生导师。广东药学会、美国化学会（ACS）成员。1994及1997年分别获武汉大学学士、硕士学位；2000年7月获中山大学生物有机化学专业博士学位。分别于2001.1-2002.1及2002.8-2003.8年在香港科技大学生物技术研究所进行访问研究；2003年底入职bm11222宝马娱乐网站工作至今。长期坚持药物化学与药理学相结合的工作方向，致力于基于靶标稳定性调控、免疫调控的抗肿瘤、AD等重大疾病的药物设计；先后主持国家自然科学基金、国家高新技术计划863项目、教育部重点科技项目、广东省自然科学基金以及中山大学百人计划引进人才“行动计划”基金等多项研究课题。在J. Med. Chem., ACS Chem. Biol., Chem. Commun., Biochem. Pharmacol., Mol. Cancer Thera.等多个专业期刊发表专业论文近百篇；申请国际国内专利20项，其中国内专利获授权15项，美国专利获授权2项。

 

研究方向

        药学多学科融合基础上的药物设计与发现：

        1.活性多肽、类天然产物库的构建；

        2.肿瘤、神经退行性疾病恶性事件中关键蛋白的降解与折叠行为调控及药理意义；

        3.重大疾病相关信号网络关键因子的探针设计与药物发现

 

科研项目

  1. 基于I型干扰素调控新机制促进肿瘤“冷-热”转换的创新药物先导物的设计与发现(82373713)，国家自然科学基金，2024.1-2027.12
  2. STING介导的抗肿瘤免疫响应调节先导药物的设计发现与抗肿瘤作用研究(2022A1515012221)，广东省基础与应用基础研究基金，2022.1-2024.12
  3. 基于ABeta聚集体重组与表面伪装策略的抗AD药物设计合成及活性研究(81973174)，国家自然科学基金，2020.1-2023.12
  4. 基于Aβ蛋白N端捕获的活性环肽设计及其抗AD作用与分子机制研究(21672266)，国家自然科学基金，2017.1-2020.12
  5. 靶向19SRP去泛素化酶的新机制蛋白酶体抑制剂的发现与抗肿瘤研究(81473083)，国家自然科学基金，2015.1-2018.12
  6. 靶向NF-kappaB/p53交叉通路网络的新型PAC类抗肿瘤活性分子的设计发现与机制研究(81172931)，国家自然科学基金，2012.1-2015.12
  7. 抑制NF-κB激活通路的新型PACs类先导物的发现、作用机制及抗肿瘤研究(30973619)，国家自然科学基金，2010.1-2012.12
  8. 神经退行性疾病信号转导及新靶标研究(批准号：9351008901000003)，广东省自然科学基金研究团队项目，2010.1-2012.12（核心成员）
  9. 多靶标内环境激活式抗耐药肿瘤先导分子的设计(2008AA02Z304)，国家高新技术863项目，2008.1-2010.12
  10. 基质细胞衍生因子衍生多肽库的构建及其抗肿瘤转移作用研究(5001773)，广东省自然科学基金，2005.1-2007.12
  11. 抑制CXCR4的重组趋化因子衍生肽库的构建及其生理意义(105133)，国家教育部重点科技项目，2005.1-2007.12
  12. 中山大学百人计划引进人才“行动计划”基金，2003年

 

代表性论文

  1. Xiaoquan Wang1, Youqiao Wang1, Anqi Cao, Qinhong Luo, Daoyuan Chen, Weiqi Zhao, Jun Xu, Qinkai Li, Xianzhang Bu* & Junmin Quan*, Development of cyclopeptide inhibitors of cGAS targeting protein-DNA interaction and phase separation. Nature Communications, 2023, 14:6132. https://doi.org/10.1038/s41467-023-41892-5
  2. Xin Yue1, Tingyu Liu1, Xuecen Wang1, Weijian Wu, Gesi Wen, Yang Yi, Jiaxin Wu, Ziyang Wange, Weixiang Zhan, Ruirui Wu, Yuan Meng, Zhirui Cao, Liyuan Le, Wenyan Qiu, Xiaoyue Zhang, Zhenyu Li, Yong Chen, Guohui Wan, Xianzhang Bu*, Zhenwei Peng*, Ran-yi Liu*, Pharmacological inhibition of BAP1 recruits HERC2 to competitively dissociate BRCA1/BARD1, suppresses DNA repair and sensitizes CRC to radiotherapy, Acta Pharmaceutica Sinica B, 2023, 13(8):3382e3399.
  3. Li Yunzhi1, Wu Jiaxin1, Jin Chaoying1, Zhang Yiqiu, Wang Jiyu, Wang Xuecen, Li Huixia, Zhang Xiaoyue, Liu Tingyu, Zhou Deyuan, Kuang Yukun, Wu Weijian, Wang Youqiao, Ke Zunfu, Bu Xianzhang*, Yue Xin*, Caged Luciferase Inhibitor-Based Bioluminescence Switching Strategy Enables Efficient Detection of Serum APN Activity and the Identification of Its Roles in Metastasis of Non-Small Cell Lung Cancer, Chem. Eur. J. 2023, e202300655
  4. Weijian Wu1, Huiying Xu1,Chenyang Liao, Youqiao Wang, Ruirui Wu, Jiaxin Wu, Wenlv Zheng, Yunzhi Li, Chaoying Jin, Yuxuan Zhao, Junmin Quan, Xin Yue*, Xianzhang Bu,* Blockade of USP14 potentiates type I interferon signaling and radiation-induced antitumor immunity via preventing IRF3 deubiquitination. Cellular Oncology (2022) 45:1347–1361
  5. Yunzhi Li1, Chaoying Jin1,Huiying Xu, Weijian Wu, Youqiao Wang, Jiaxin Wu, Tingyu Liu, Guohui Wan, Xin Yue,* and Xianzhang Bu*, Identification of 2‑Benzylidene-tetralone Derivatives as Highly Potent and Reversible Firefly Luciferase Inhibitors. ACS Med. Chem. Lett. 2022, 13, 304−311
  6. Haixia Sun, Daoyuan Chen, Sirui Zan, Weijian Wu, Huiying Xu, Chunxiang Luo, Hui Su, Yanqiao Feng, Weiyan Shao, Arabella Wan, Binhua Zhou, Guohui Wan * and Xianzhang Bu* Design and Discovery of Natural Cyclopeptide Skeleton Based Programmed Death Ligand-1 Inhibitor as Immune Modulator for Cancer Therapy, Journal of Medicinal Chemistry 2020, 63, 11286−11301
  7. Yanqiao Feng1,Hui Su1, Yunzhi Li, Chunxiang Luo, Huiying Xu, Youqiao Wang, Haixia Sun, Guohui Wan, Binhua Zhou* and Xianzhang Bu* Degradation of intracellular TGF-b1 by PROTACs efficiently reverses M2 macrophage induced malignant pathological events. Chem. Commun., 2020, 56, 2881−2884
  8. Yan, S.; Sun, H.; Bu, X.*; Wan, G.* New strategy for COVID-19: an evolutionary role for RGD motif in SARS-CoV-2 and potential inhibitors for virus infection. Front Pharmacol. 2020, 11, 912.
  9. Liu, Ziyi; Wang, Youqiao; Qin, Wenjing; Chen, Daoyuan; Feng, Yanqiao; Su, Hui; Shao, Weiyan; Zhou, Binhua; Bu, Xianzhang, Raloxifene alleviates amyloid-beta-induced cytotoxicity in HT22 neuronal cells via inhibiting oligomeric and fibrillar species formation. Journal of biochemical and molecular toxicology, 2019, e22395
  10. Daoyuan Chen, Wenjing Qin, Gesi Wen, Bihua Shi, Ziyi Liu, Youqiao Wang, Qiang Zhou, Junmin Quan, Binhua Zhou*, Xianzhang Bu*, Dissociation of haemolytic and oligomerpreventing activities of gramicidin S derivatives targeting the amyloid-β N-terminus, Chem. Commun., 2017, 53, 13340–13343
  11. Gesi Wen1, Daoyuan Chen1, Wenjing Qin, Binhua Zhou, Youqiao Wang, Ziyi Liu, Jun Du, Qiang Zhou, Junmin Quan, Xianzhang Bu*, Stabilizing of Amyloid-β Peptide by the N-terminus Capture is Capable of Preventing and Eliminating Amyloid-β Oligomers. Chem. Commun., 2017, 53, 7673−7676
  12. Xin Yue1, Yinglin Zuo1, Hongpeng Ke, Jiaming Luo, lanlan Lou, Wenjing Qin, Youqiao Wang, Ziyi Liu, Daoyuan Chen, Haixia Sun, Weichao Zheng, Cuige Zhu, Ruimin Wang, Gesi Wen, Jun Du, Binhua Zhou*, Xianzhang Bu*, Identification of 4-arylidende curcumin analogues as novel proteasome inhibitors for potential anticancer agents targeting 19S regulatory particle associated deubiquitinase. Biochem Pharmacol 2017, 137, 29–50.
  13. Gesi Wen, Wenjing Qin, Daoyuan Chen, Youqiao Wang, Xin Yue, Ziyi Liu, Yingnan Cao, Jun Du, Binhua Zhou*, and Xianzhang Bu*, Stabilizing the monomeric amyloid-β peptide by Tyrocidine A prevents and reverses the amyloideogenesis without the accumulation of oligomers Chem. Commun., 2017, 53, 3886–3889.

  14. Baoxia Liang, Ziyi Liu, Yingnan Cao, Cuige Zhu, Yinglin Zuo, Lei Huang, Gesi Wen, Nana Shang, Yu Chen, Xin Yue, Jun Du, Baojian Li, Binhua Zhou*, Xianzhang Bua*, MC37, a new mono-carbonyl curcumin analog, induces G2/M cell cycle arrest and mitochondria-mediated apoptosis in human colorectal cancer cells. European Journal of Pharmacology 2016, 796,139–148.

  15. Jianyong Zhu, Ruimin Wang, Lanlan Lou, Wei Li, Guihua Tang, Xianzhang Bu*, and Sheng Yin*, Jatrophane Diterpenoids as Modulators of P-Glycoprotein-Dependent Multidrug Resistance (MDR): Advances of Structure–Activity Relationships and Discovery of Promising MDR Reversal Agents, J. Med. Chem., 2016, 59(13):6353–6369

  16. Baoxia Liang, Weiyan Shao, Cuige Zhu, Gesi Wen, Xin Yue, Ruimin Wang, Junmin Quan, Jun Du, and Xianzhang Bu*, Mitochondria-Targeted Approach: Remarkably Enhanced Cellular Bioactivities of TPP2a as Selective Inhibitor and Probe toward TrxR, ACS Chem. Biol., 2016, 11 (2), 425–434

  17. Zhang-Hua Sun, Yu Chen, Yan-Qiong Guo, Jie Qiu, Cui-Ge Zhu, Jing Jin, Gui-Hua Tang, Xian-Zhang Bu*, Sheng Yin*, Isolation and cytotoxicity evaluation of taxanes from the barks of Taxus wallichiana var. mairei, Bioorganic & Medicinal Chemistry Letters, 2015, 25, 1240–1243

  18. Cuige Zhu, Yinglin Zuo, Baoxia Liang, Hong Yue, Xin Yue, Gesi Wen, Ruimin Wang, Junmin Quan, Jun Du and Xianzhang Bu* Distinct tubulin dynamics in cancer cells explored using a highly tubulin-specific fluorescent probe，Chem. Commun., 2015,  51, 13400–13403.

  19. Cuige Zhu , Yinglin Zuo , Ruimin Wang , Baoxia Liang , Xin Yue , Gesi Wen , Nana Shang , Lei Huang , Yu Chen , Jun Du , and Xianzhang Bu * Discovery of Potent Cytotoxic Ortho-Aryl Chalcones as New Scaffold Targeting Tubulin and Mitosis with Affinity-Based Fluorescence，J. Med. Chem., 2014, 57 (15), 6364–6382.

  20. L. Huang, Y. Chen, B. Liang, B. XING, G. Wen, S. Wang, X. Yue, C. Zhu, J. Du and X. Bu, Furanyl Acryl Conjugated Coumarin as Efficient Inhibitor and Highly Selective Off-On Fluorescent Probe for Covalent Labelling of Thioredoxin Reductase Chem. Commun., 2014,  50, 6987–6990.

  21. Nana Shanga, Yongxian Shao, Yinghong Cai, Matthew Guan, Manna Huang, Wenjun Cui, Lin He, Yan-Jun Yu, Lei Huang, Zhe Li, Xianzhang Bu*, Hengming Ke*, Hai-Bin Luo*, Discovery of 3-(4-hydroxybenzyl)-1-(thiophen-2-yl)chromeno[2,3-c]pyrrol-9(2H)- one as a phosphodiesterase-5 inhibitor and its complex crystal structure, Biochemical Pharmacology 2014, 89, 86–98 .

  22. H. Liu, Y. Liu, F. Zhang, H. Wang, G. Zhang, B. Zhou, Y. Zuo, S. Cai, X. Bu* and J. Du*, Identification of potential pathways involved in induction of cell cycle arrest and apoptosis by a new 4-arylidene Curcumin analogue T63 in lung cancer cells: a comparative proteomic analysis Mol. BioSyst., 2014, 10, 1320–1331.

  23. Binhua Zhou, Yinglin Zuo, Baojian Li, Hao Wang, Hao Liu, Xianfeng Wang, Xu Qiu, Yun Hu, Shijun Wen, Jun Du, Xianzhang Bu*, Deubiquitinase Inhibition of 19S Regulatory Particles by 4-Arylidene Curcumin Analogue AC17 Causes NF-κB Inhibition and p53 Reactivation in Human Lung Cancer Cells, Molecular Cancer Therapeutics, 2013, 12(8), 1381–1392.

  24. Yun Hu, Yaqi Yang, Yanjun Yu, Gesi Wen, Nana Shang, Wei Zhuang, Dihan Lu, Binhua Zhou, Xin Yue, Baoxia Liang, Jun Du, Feng Li, Xian-Zhang Bu*, Synthesis and Identification of New Flavonoids Targeting Liver X Receptor β Involved Pathway as Potential Facilitators of Aβ Clearance with Reduced Lipid Accumulation. Journal of Medicinal Chemistry, 2013, 56, 6033–6053.

  25. Binhua Zhou, Jianing Huang, Yinglin Zuo, Baojian Li, Qiang Guo, Baicheng Cui, Weiyan Shao, Jun Du, Xianzhang Bu*, 2a, a novel curcumin analogue, sensitizes cisplatin-resistant A549 cells to cisplatin by inhibiting thioredoxin reductase concomitant oxidative stress damage, European Journal of Pharmacology, 2013, 707, 130–139.

  26. Hao Liu, BinHua Zhou, Xu Qiu, HongSheng Wang, Fan Zhang, Rui Fang, XianFeng Wang, ShaoHui Cai, Jun Du*, XianZhang Bu*，T63, a new 4-arylidene curcumin analogue,induces cell cycle arrest and apoptosis through activation of the reactive oxygen species–FOXO3a pathway in lung cancer cells，Free Radical Biology and Medicine, 2012, 53, 2204–2217.

  27. Yinglin Zuo, Jianing Huang, Binhua Zhou, Shuni Wang, Weiyan Shao, Cuige Zhu, Li Lin, Gesi Wen, Hongyang Wang, Jun Du, Xianzhang Bu*  Synthesis, cytotoxicity of new 4-arylidene curcumin analogues and their multi-functions in inhibition of both NF-kB and Akt signaling, Europe Journal of Medicinal Chemistry, 2012, 55, 346–357.

  28. Yinglin Zuo, Yi Yu, Shuni Wang, Weiyan Shao, Binhua Zhou, Li Lin, Zhuoyu Luo, Ruogu Huang, Jun Du, Xianzhang Bu* Synthesis and cytotoxicity evaluation of biaryl-based chalcones and their potential in TNFa-induced nuclear factor-kB activation inhibition Europe Journal of Medicinal Chemistry, 2012, 50, 393–404.

  29. Yanjun Yu, Yun Hu, Weiyan Shao, Jianing Huang, Yinglin Zuo, Yingpeng Huo, Linkun An, Jun Du, and Xianzhang Bu* Synthesis of Multi-Functionalized Chromeno[2,3-c]pyrrol-9(2H)-ones: Investigation and Application of Baker–Venkataraman Rearrangement Involved Reactions Catalyzed by 4-(Dimethylamino)pyridine, Europe Journal of Organic Chemistry, 2011, 4551–4563.

  30. X Qiu, YH Du, B Lou, YL Zuo, WY Shao, YP Huo, JL Huang, YJ Yu, BH Zhou,J Du， HA Fu* and  XZ Bu*, Synthesis and Identification of New 4-Arylidene Curcumin Analogues as Potential Anticancer Agents Targeting Nuclear Factor-kB Signaling Pathway. J Med Chem, 2010. 53 (23), 8260–8273.

  31. MG Yuan, MX Luo, Y Zhang, X Qiu, J Gui, Y Cao, X. Bu*, YL Ren* and XP Hu, Identification of curcumin derivatives as human glyoxalase I inhibitors: A combination of biological evaluation, molecular docking, 3D-QSAR and molecular dynamics simulation studies Bioorg & Med Chem  2011,19(3):1189–1196

  32. Z Xiao, LM Lin, ZH Liu, FT Jia, WY Shao, MJ Wang,L Liu, SL Li, F Li* and Bu, X.*, Potential Therapeutic Effects of Curcumin: Relationship to Microtubule- associated Proteins 2 in Abeta1-42 Insult. Brain Res  2010, 1361, 115–123

  33. Y.Huo, X Qiu, WY Shao, JN Huang, YJ Yu, YL Zuo, LK An, J Du and Bu, X.* , New fluorescent trans-dihydrofluoren-3-ones from aldol-Robinson annulation- regioselective addition involved one-pot reaction. Org Biomol Chem 2010. 8, 5048–5052

  34. Shen, Y.D., Tian Y.X, Bu, X. Z.* and L.Q. Gu, Natural tanshinone-like heterocyclic-fused ortho-quinones from regioselective Diels-Alder reaction: Synthesis and cytotoxicity evaluation. Eur J Med Chem 2009, 44, 3915–3921.

  35. Ying Peng Huo, Xu Qiu, Wei Yan Shao, Lin Kun An, Xian Zhang Bu *, Lian Quan Gu; Synthesis of new 2-aryl-6-styryl-2,3- dihydropyridin-4(1H)-one derivatives from curcuminoids. Chinese Chemistry Letters, 2009, 20, 1291–1295

  36. Qiu, X.; Liu, Z.; Shao, W.Y.; Liu,X.; Jing, D.P.; Lu, Y.J.; An, L.K.; Huang, S.L.; Bu, X.Z.*; Huang, Z. S.; Gu, L.Q., Synthesis and evaluation of curcumin analogues as potential thioredoxin reductase inhibitors. Bioorgan Med Chem 2008, 16, 8035–8041.

  37. Shao, W.Y.; Cao, Y.N.; Yu, Z.W.; Pan, W.J.; Qiu, X.; Bu, X.Z.*; An, L. K.; Huang, Z. S.; Gu, L.Q.*; Chan, A. S. C. Facile preparation of new unsymmetrical curcumin derivatives by solid-phase synthesis strategy. Tetrahedron Lett 2006, 47, 4085–4089.

  38. Pei, L. X.; Li, Y.M.; Bu, X.Z.*; Gu, L.Q.; Chan, A. S. C. One-pot synthesis of 5,6-dihydroxylated benzo[b]furan derivatives. Tetrahedron Lett 2006, 47, 2615–2618.

  39. Shen, Y.D.; Wu, H.Q.; Zhang, S.L.; Bu, X.Z.*; An, L.K.; Huang, Z.S.; Liu, P.Q.; Gu, L.Q.; Li, Y.M. and Chan, A.S.C. Novel synthesis of o-naphthothiophenequinone derivatives via regioselective Diels-Alder reaction. Tetrahedron 2005, 61, 9097–9101.

  40. Pei, L.X.; Huang, S.L.; Shen, Y.D.; An, L.Q.; Huang, Z.S.; Li, Y.M.; Gu, L.Q.*; Bu, X.Z.* and Chan, A.S.C. Synthesis of novel dihydrofuro[b]-pyridinone derivatives: oxidation coupling of 3-hydroxy-4(1H)-pyridinone with beta-dicarbonyl compounds. Tetrahedron Lett 2005, 46, 5085–5088.

  41. Bu, X.Z.; Wu, X.M.; Ng, N.L.J.; Mak, C.K.; Qin, C.G.; Guo, Z.H. Synthesis of gramicidin S and its analogues via an on-resin macrolactamization assisted by a predisposed conformation of the linear precursors. J Org Chem 2004, 69, 2681–2685.

  42. Bu, X.Z.; Xie, G.Y.; Law, C.W.; Guo, Z.H. An improved deblocking agent for direct Fmoc solid-phase synthesis of peptide thioesters. Tetrahedron Lett 2002, 43, 2419–2422.

  43. Bu, X.Z.; Wu, X.M.; Xie, G.Y.; Guo, Z.H. Synthesis of tyrocidine A and its analogues by spontaneous cyclization in aqueous solution. Org Lett 2002, 4, 2893-2895.

  44. Bu, X.Z.; Huang, Z.S.; Zhang, M.; Ma, L.; Xiao, G.W.; Gu, L.Q. Synthesis of new 1,1-dimethyl-1,2,3,4-tetrahydrophenanthrene derivatives. Tetrahedron Lett 2001, 42, 5737–5740. 

 

主要发明专利

  1. 卜宪章，王尤桥，张怡秋，一种促进 Aβ 清除的化合物及其制备方法和应用，申请日, 2024-01-15, 中国, 202410054079.X

  2. 卜宪章，岳欣，徐慧莹，伍伟健，一种多芳乙烯β-二酮类化合物或其药学上可接受的盐及其应用，授权日, 2023-11-07, 中国, ZL202111250655.0

  3. 卜宪章，李运之，金超颖，一类2-亚苄基四氢萘酮衍生物及其制备方法和应用，授权日, 2023-06-09, 中国, ZL202210000915.7

  4. 卜宪章，孙海霞，伍伟健，一种环肽化合物及其应用,授权日, 2022-03-11, 中国, ZL202010840057.8

  5. 卜宪章，李运之，粟慧，冯艳巧，周斌华，一种可促进 TGF-β1 蛋白靶向降解的化合物及其制备方法与应用, 授权日, 2021-07-06, 中国, CN201911031379.1.

  6. 万国辉，牛艺，卜宪章，一种磺胺间甲氧嘧啶衍生物在制备抗肿瘤药物中的应用, 授权日, 2021-05-25, 中国, CN202010232655.7.

  7. 卜宪章，陈道远，温格思，秦文静，周斌华，一类环十肽分子及其应用, 授权日,2020-09-04，中国, ZL201710104115.9.

  8. Xianzhang Bu, Cuige Zhu, Xin Yue, Yinglin Zuo, Yu Chen, Gesi Wen, o-phenyl chalcone compounds and uses thereof, 美国, US 9663542 B2；PCT申请日：2015.1.14,美国申请日：2016.11.17，授权日：2017.5.30

  9. Xianzhang Bu, Cuige Zhu, Xin Yue, Yinglin Zuo, Yu Chen, Gesi Wen, o-phenyl chalcone compounds and uses thereof, 美国, US 9988405 B2；PCT申请日：2015.1.14,美国申请日：2016.11.17，授权日：2018.6.5

  10. 卜宪章，朱翠革，岳欣，左应林，陈雨，温格思，邻苯基查尔酮类化合物及其制备方法和应用，申请号：PCT/CN2015/070651，申请日期：2015.01.14；国际专利PCT申请

  11. 卜宪章，朱翠革，左应林，杜军，温格思，岳欣，陈雨，一种邻苯基查尔酮类化合物在荧光探针中的应用，申请号：201410353793.5；申请日期：2014.07.23，授权公告日，2017.05.27

  12. 卜宪章，朱翠革，岳欣，左应林，陈雨，温格思，邻苯基查尔酮类化合物及其制备方法和应用，申请号：201410032845.9；申请日期：2014.01.23，授权公告日，2016.06.08

  13. 卜宪章，吴海强，黄磊，陈雨，一种硫氧还蛋白还原酶荧光探针及其制备方法和用途，申请号：201410137070.1；申请日期：2014.04.08，授权公告日：2017.01.04

  14. 卜宪章，罗海彬，商娜娜，于艳君，杜军，李哲，蔡颖红，邵咏贤，何琳，一种取代吡咯色原酮类化合物在制备治疗5型磷酸二酯酶相关疾病的药物中的应用，申请号：201310017288.9；申请日期：2013.01.17, 授权公告日：2015.8.26

  15. 卜宪章，刘培庆，于艳君，汪煜华，胡云，邵伟艳，杜军，羟基取代的黄酮类化合物及其制备方法和应用。中华人民共和国知识产权局。申请号：201110269084.5.申请日期：2011年9月13日

  16. 卜宪章，胡云，于艳君，杜军，邵伟艳，商娜娜，庄玮，陆迪涵，刘巍，陈艺贞，温格思，氨基取代的黄酮类化合物及其制备方法和应用。中华人民共和国知识产权局。申请号：201110269753.9 申请日期：2011年9月13日, 授权公告日：2014.6.11

  17. 卜宪章，左应林，杜军，温格思，周斌华，商娜娜，芳基取代查尔酮类化合物及其制备方法和应用 中国专利申请号：201110217094.4 授权公告日：2013年12月25日

  18. 卜宪章，于艳君，邵伟艳，胡云，黄壮裕，左应林，一种多多取代色原酮并吡咯环类衍生物及其合成方法和应用，中国发明专利，专利号：ZL200910214553.6，申请日：2009.12.31 授权公告日：2012.6.27

  19. 卜宪章，仇旭，霍应鹏，于艳君，金达平，古练权，具有抗肿瘤作用的多芳乙烯取代beta-二酮类化合物，中国发明专利，申请号：200810220580.X, 申请日：2008.12.30，授权公告号 CN101700995B, 授权公告日：2013.06.05

  20. 卜宪章，邵伟艳，古练权，曹颖男，于志文，一种合成多肽及其应用,中国发明专利,专利号:ZL 200410077777.4, 授权公告日：2007.2.21